Talphera

Talphera P/B

The P/B (Price-to-Book Ratio) of Talphera (TLPH) as of Nov 12, 2026 is 2.22. In the previous year, P/B (Price-to-Book Ratio) was 4.72 — a change of -53.03% (lower).

P/B

2.22

YoY

-53.03%

Last updated:

P/B (Price-to-Book Ratio) of Talphera is 2025 2.22 . P/B (Price-to-Book Ratio) of Talphera was 2024 4.72 . It decreases by -53.03% lower compared to the previous year.

The Talphera P/B history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/B
Date
P/B
Jan 1, 2018
8.89 USD
Jan 1, 2019
-0.91 USD
Jan 1, 2020
-0.68 USD
Jan 1, 2021
-1.05 USD
Jan 1, 2022
1.73 USD
Jan 1, 2023
2.68 USD
Jan 1, 2024
4.72 USD
Jan 1, 2025
2.22 USD
The Talphera P/B history
YEARP/BYoY
2.22-53.03%
4.72+76.29%
2.68+54.65%
1.73-264.54%
-1.05+55.32%
-0.68-25.71%
-0.91-110.27%
8.89-958.43%
-1.04-85.38%
-7.08-720.44%
1.14+40.90%
0.81—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Talphera Stock analysis

What does Talphera do? Talphera Inc develops and commercializes therapies for medically supervised settings, focusing on nafamostat-based products. The company's Niyad targets regional anticoagulants for dialysis circuits in acute kidney injury and chronic kidney disease patients. LTX-608 is an intravenous formulation for potential treatment of viral infections, ARDS, DIC, and acute pancreatitis. Pre-filled syringes Fedsyra and PFS-02 are also under development. The firm sells these products to hospitals, dialysis centers, and medical facilities requiring specialized therapies in controlled environments. Niyad is designed for use during continuous renal replacement therapy and hemodialysis procedures, primarily targeting healthcare providers in hospital settings and dialysis centers. LTX-608 aims to address viral and inflammatory conditions, with potential buyers including hospitals treating respiratory and coagulation disorders. The pre-filled syringes Fedsyra and PFS-02 serve as delivery systems for these therapies, appealing to medical institutions needing efficient administration solutions. The company's revenue streams come from the sale of Niyad, LTX-608, Fedsyra, and PFS-02 to healthcare providers. Hospitals and dialysis centers are key buyers for Niyad, while LTX-608 targets hospitals managing viral outbreaks and severe inflammatory conditions. Fedsyra and PFS-02 are sold as complementary products to support the delivery of nafamostat therapies, with demand driven by the need for specialized medical treatments in supervised care settings. Talphera is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Talphera stock

P/B (Price-to-Book Ratio) of Talphera is 2.22 in 2025.

P/B (Price-to-Book Ratio) of Talphera changed from 4.72 to 2.22, representing a -53.03% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of P/B (Price-to-Book Ratio) Talphera since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Book ratio compares a company's market price to its book value. A low P/B may indicate an undervalued stock, while a high P/B could suggest overvaluation or strong growth expectations.

P/B = Stock Price / Book Value per Share

To evaluate P/B (Price-to-Book Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/B (Price-to-Book Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/B (Price-to-Book Ratio)'s Talphera with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Talphera

All Key Metrics — Talphera